Reduced brain glutamate in patients with Parkinson's disease
Reduced brain glutamate in patients with Parkinson's disease
复制标题
DOI：
10.1002/nbm.1203
复制
发表时间：
2008-05-01
影响因子：
2.9
通讯作者：
den Hollander, Jan A.
中科院分区：
文献类型：
--
作者：
Griffith, H. Randall;Okonkwo, Ozioma C.;den Hollander, Jan A.
对谷氨酸(Glu)在特发性帕金森病(PD)中所起作用的了解仍然有些难以捉摸。帕金森病的动物模型表明，Gin受体的过度活动使帕金森病的运动症状复杂化，谷氨酸阻断可能是帕金森病的一个药理靶点，而患者的尸检研究证明，谷氨酸的变化不那么令人信服。以前没有H-1MRS患者的研究记录了谷氨酸的变化。除一项研究外，所有这些先前的研究都是在1.5T下进行的。我们对12名非痴呆帕金森病患者和12名年龄匹配、神经学正常的受试者进行了3TH-1MRS检查。以肌酸+磷酸肌酸(Cr)为参比，从单体素质子磁共振波谱中测定了谷氨酸，N-乙酰天冬氨酸(NAA)和胆碱类化合物(CHO)。结果显示，PD患者血清谷氨酸/肌酸比值明显低于正常对照组(t=2.54，P=0.019)，而NAA/Cr和Cho/Cr比值与正常对照组相比无明显差异。这些发现表明帕金森病患者大脑皮层中的谷氨酸减少。在未来的研究中，应该研究3T时的H-1MRS，作为追踪PD患者代谢脑变化过程与疾病进展相关的一种手段。版权所有(C)2007 John Wiley&Sons，Ltd.
An understanding of the role played by glutamate (Glu) in idiopathic Parkinson's disease (PD) has remained somewhat elusive. Animal models of PD suggest that over-activity of Gin receptors complicates the motor symptoms of PD and that Glu blockade may be a pharmacologic target in PD, whereas patient autopsy studies have proved less convincing for changes in Glu. No previous H-1 MRS patient studies have documented changes in glutamate. All but one of these previous studies were performed at 1.5 T. We performed 3T H-1 MRS of the posterior cingulate gyrus in 12 non-demented patients with PD and 12 age-matched, neurologically normal control participants. Glu, N-acetylaspartate (NAA) and choline-containing compounds (Cho) measured in reference to creatine + phosphocreatine (Cr) were determined from single-voxel proton MR spectra measured by PRESS at TE of 80 ms. The results show that the Glu/Cr ratio was reduced in patients with PD compared with controls (t = 2.54; P = 0.019), whereas no differences were observed in NAA/Cr or Cho/Cr ratios. These findings suggest that a reduction in Glu occurs in the cerebral cortex of patients with PD. H-1 MRS at 3 T should be investigated in future studies as a means of tracking the course of metabolic brain changes in association with progression of disease in patients with PD. Copyright (C) 2007 John Wiley & Sons, Ltd.